U.S. Markets open in 3 hrs 4 mins

Tagrisso: AstraZeneca’s Top-Selling Drug in Q1

Margaret Patrick
Tagrisso: AstraZeneca’s Top-Selling Drug in Q1

AstraZeneca's (AZN) Tagrisso was approved by the FDA first for the treatment of epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer and then as a first-line therapy for EGFR-mutated NSCLC. The drug has become the highest-selling drug in AstraZeneca’s portfolio.